General Western Blot Reagents
Abcam Ledol, Antifungal agent, 500MG
MW 222.37 Da, Purity >95%. Antifungal agent. Putative anti-inflammatory and antinociceptive agent. May show expectorant, anti-inflammatory, antitussive and antinociceptive effects in vivo. Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BMS 345541, IKK-2 and IKK-1 inhibitor, 10MG
MW 255.32 Da, Purity >98%. Highly selective cell permeable IKK-2 and IKK-1 inhibitor (IC₅₀ values are 0.3 and 4 μM for IKK-2 and IKK-1 respectively). Blocks NF-κB-dependent transcription. Shows anti-inflammatory and radiosensitizing effects in vivo. Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam 1400W, iNOS inhibitor, 10MG
MW 250.17 Da, Purity >97%. Selective iNOS inhibitor, 5000-fold selective over eNOS (Kd values are ≤7 nM, 2 μM and 50 μM at human iNOS, nNOS and eNOS, respectively).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Do x ycycline hyclate, matri x metalloprotease inhibitor, 5G
MW 1025.9 Da, Purity >97%. Synthetic tetracycline; matrix metalloprotease (MMP) inhibitor. Inhibits tumour growth, suppresses cell proliferation and induces apoptosis in vitro and in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Acetylcysteine (N-Acetyl-L-cysteine), ROS inhibitor, 50MG
MW 163.2 Da, Purity >99%. ROS inhibitor. L-cysteine prodrug. Mucolytic agent. Inhibits viral stimulation by reactive oxygen intermediates. Shows mucolytic, hepatoprotective and antiviral effects in vivo. Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SAG (Smo agonist), Smoothened agonist, 5MG
MW 490.1 Da, Purity >98%. Cell-permeable, selective, potent Smoothened agonist (EC₅₀ = 3 nM). Binds the Smo heptahelical bundle that antagonizes cyclopamine (ab120392) action. Active in vitro and in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam B-Phycoerythrin Conjugation Kit - Lightning-Link, 3 x 60UG
Labeling in < 4 hrs with 30 secs hands-on time using B-Phycoerythrin Conjugation Kit - Lightning-Link ab102871. 100% antibody recovery.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Anhydrotetracycline hydrochloride, Tetracycline repressor, 500MG
MW 462.9 Da, Purity >98%. Tetracycline repressor and reverse tetracycline repressor effector. Tetracycline (ab141223, ab146579) derivative. Tetracycline-dependent gene expression effector in bacterial expression systems. Binds poorly to the 30S ribosomal subunit. Exhibits no antibiotic activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Triacsin C, acyl-CoA synthetase inhibitor, 1MG
MW 207.27 Da, Purity >90%. Potent, specific acyl-CoA synthetase inhibitor (Ki values are 15 nM and 2 μM for Faa2p and Faa4p respectively). Inhibits synthesis of cholesteryl ester and triacylglycerol in vitro. Vasodilator agent. Orally active. Active in vivo and in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam N-Acetyl-D-glucosamine, N-Acetyl derivative of glucosamine, 25G
MW 221.21 Da, Purity >98%. Monosaccharide derivative of glucose found in polymers of bacterial cell walls, chitin, hyaluronic acids and various glycans. Used to identify, differentiate and characterize N-acetyl-β-D-hexoaminidase(s).
The product is subject to the following: Abcam Restricted Use Statement
Abcam LM11A-31, nonpeptide p75NTR ligand, 5MG
MW 316.26 Da. Selective nonpeptide p75NTR ligand. Blocks p75-mediated cell death. Promotes neurogenesis and neurite survival. Does not affect NGF binding to TrkA. Shows neuroprotective and neuroregenerative effects *in vivo.* Orally active. Blood-brain barrier permeable.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Doceta x el, Cytoto x ic agent, 10MG
MW 807.9 Da, Purity >99%. Potent cytotoxic agent in vitro (IC₅₀ = 2 nM). Disrupts microtubule assembly and arrests cell divison at G₂/M phase. Induces apoptosis. Antitumor agent. Active in vivo and in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ghrelin (human), Endogenous GHS agonist, 1MG
MW 3370.91 g/mol, Purity >95%. Endogenous agonist peptide for the ghrelin (GHS) receptor. Stimulates release of growth hormone from the pituitary gland and regulates feeding, appetite, growth and energy homeostasis.
The product is subject to the following: Abcam Restricted Use Statement
Abcam tBuBHQ (BHQ), Sarco-endoplasmic reticulum Ca2+-ATPase (SERCA) inhibitor, 100MG
MW 222.32 Da, Purity >99%. Sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Tamo x ifen citrate, Estrogen receptor antagonist and partial agonist, 100MG
MW 563.65 g/mol, Purity >99%. Competitive estrogen receptor antagonist and partial agonist. Inhibits estrogen dependent gene transcription and tumor growth. Additionally decreases cardiac infarction and inhibits Kir2.1, Kir2.2 and Kir2.3 potassium channels (IC₅₀ values are 0.93, 0.87 and 0.31 μM, respectively).
The product is subject to the following: Abcam Restricted Use Statement